Use of platelet activating factor acetylhydrolase as a biomarker for anaphylaxis

US 8,562,982, assigned to Allertech Labs Inc, relates to medical technology, and is available for sale through IPApproach.

US Patents

1 granted

Assignee

Allertech Labs Inc

Availability

For Sale

Patents Included

• US 8,562,982↗

Technology Highlights

• Establishes PAF-AH activity as a predictive biomarker for severe and fatal anaphylaxis
• Enables risk stratification prior to acute anaphylactic events
• Supports diagnostic assays using patient samples compared against reference values
• Allows early identification of high-risk patients in clinical and emergency settings
• Covers therapeutic intervention, including increasing serum PAF-AH levels
• Includes methods for treatment and prevention, not just detection
• Applicable to drug development, companion diagnostics, and emergency protocols
• Addresses a high-mortality, under-served clinical condition
• Broad applicability across food allergies, drug allergies, insect stings, and idiopathic anaphylaxis

Overview

The patent covers the use of PAF-AH activity levels as a biomarker to identify, predict, and manage severe or fatal anaphylaxis. The invention establishes a clinically actionable correlation between low PAF-AH activity and heightened anaphylaxis risk, enabling early diagnosis, risk stratification, and targeted therapeutic intervention.

The IP further encompasses methods of treatment and prevention, including administration of PAF-AH and/or PAF receptor antagonists.

This technology is applicable across diagnostics, allergy and immunology, emergency medicine, pharmaceuticals, biologics, and point-of-care testing, addressing a critical unmet medical need in life-threatening allergic reactions.

Listing updated August 21, 2026

IPApproach lists patents and portfolios where the seller has not requested anonymity or confidentiality. Patent numbers link to public records on Google Patents.